HC Wainwright Has Bullish Outlook for Savara FY2026 Earnings

Key Points

• HC Wainwright has revised its FY2026 earnings per share estimate for Savara to ($0.38), reflecting an improvement from the previous estimate of ($0.41).
• Despite the revised estimate, the consensus among analysts for Savara's current full-year earnings remains at ($0.45) per share, indicating potential challenges ahead.
• Currently, Savara has a "Buy" rating from HC Wainwright, with a price target set at $8.00, while other analysts have varied ratings and price targets ranging from $2.00 to $7.00.

Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Savara in a research note issued on Wednesday, September 3rd. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.38) per share for the year, up from their previous estimate of ($0.41). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara's FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.50 EPS.

Other analysts also recently issued research reports about the company. Guggenheim restated a "buy" rating and set a $8.00 price objective (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Oppenheimer boosted their price objective on Savara from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, August 15th. Wells Fargo & Company cut their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Finally, Evercore ISI dropped their target price on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.67.

Savara Trading Up 3.9%

NASDAQ SVRA traded up $0.14 on Friday, hitting $3.72. 2,476,564 shares of the company were exchanged, compared to its average volume of 1,779,894. The company's 50 day moving average price is $2.71 and its 200-day moving average price is $2.71. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. The firm has a market capitalization of $642.96 million, a P/E ratio of -7.44 and a beta of 0.56. Savara has a twelve month low of $1.89 and a twelve month high of $4.70.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02).

Hedge Funds Weigh In On Savara

Hedge funds have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Savara by 24.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock worth $482,000 after buying an additional 31,168 shares during the last quarter. Millennium Management LLC increased its holdings in Savara by 71.8% in the fourth quarter. Millennium Management LLC now owns 482,263 shares of the company's stock worth $1,481,000 after buying an additional 201,599 shares during the last quarter. Deutsche Bank AG increased its holdings in Savara by 6.1% in the fourth quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock worth $2,848,000 after buying an additional 53,054 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Savara by 314.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock worth $217,000 after buying an additional 53,547 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Savara by 25.3% in the first quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company's stock worth $92,000 after buying an additional 6,532 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Insider Buying and Selling

In other news, Director Richard J. Hawkins acquired 48,225 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares of the company's stock, valued at approximately $235,550.64. This represents a 71.72% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.13% of the company's stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.